Silence Therapeutics ($SLN) Stock Hub: SANRECO Follow-Up, Completed Offering and Phase 3 Plans

01Executive Summary

Silence Therapeutics is no longer a pre-readout, single-catalyst setup. The randomized SANRECO Phase 2 study produced a large controlled effect: 88% of divesiran-treated patients met the primary responder definition versus 19% on placebo, with p<0.0001. The responder definition was clinically concrete—no phlebotomy and haematocrit below 45% during weeks 18 through 36—rather than a biomarker-only endpoint.

The less frequent regimen also worked. Response was 93.8% every six weeks and 81.3% every twelve weeks. Mean phlebotomies were 0.2 with divesiran versus 2.1 with placebo, while haematocrit, ferritin and patient-reported MPN-SAF Total Symptom Score moved in the expected direction. The company reported no new safety findings; injection-site reactions were infrequent and self-limiting, and two investigator-reported anaemia cases were Grade 1.

The remaining clinical uncertainty is different, not gone. Forty-eight patients cannot establish uncommon safety events, long-term durability, Phase 3 effect size or commercial uptake. Full results are still intended for a medical congress, and all participants are now in a three-year blinded/open-label extension. Silence plans a Phase 3 start in the first half of 2027 using the Q12W regimen versus placebo.

Q2 liquidity was US$72.1 million, Q2 R&D was US$9.1 million and net loss was US$12.3 million. One day after the data, Silence priced an upsized US$175 million public offering of 12,962,963 ADS at US$13.50. That converts a previously constrained balance sheet into a Phase 3-capable one, at the price of substantial ownership dilution.

02What The Company Actually Is Today

Silence Therapeutics plc is a London-based clinical-stage siRNA company listed on Nasdaq through American Depositary Shares. Its mRNAi GOLD chemistry is designed to silence liver-expressed disease targets through infrequent subcutaneous dosing. After SANRECO, the company is best understood as a Phase 3 haematology developer with two cardiovascular partnering options rather than as a broad platform story.

There is still no product revenue. Q2 revenue was zero and first-half collaboration revenue was US$0.422 million. The key economic assets are the probability-adjusted value of divesiran, potential partnering terms for zerlasiran, the post-offering cash balance and the cost required to reach the next clinical proof.

03Divesiran And The Positive SANRECO Readout

Polycythaemia vera is a myeloproliferative neoplasm in which excess red-cell production requires many patients to undergo repeated therapeutic phlebotomy to keep haematocrit below 45%. Divesiran silences TMPRSS6, raises hepcidin and restricts iron availability for erythropoiesis. The intended clinical benefit is fewer procedures, better iron stores and lower symptom burden without creating clinically important anaemia.

The central commercial result is the Q12W arm. An every-twelve-week injection that preserves haematocrit control and reduces phlebotomy burden would be easier to differentiate than a more frequent regimen. The numerical gap between Q6W and Q12W still matters, however: Phase 3 must show that convenience does not trade away too much efficacy.

The next evidence layers are full congress-level data, the three-year extension, regulatory feedback and the Phase 3 protocol. Important details include baseline phlebotomy burden, confidence intervals, subgroup consistency, duration after the last dose, anaemia thresholds, discontinuations and how rescue phlebotomy is handled.

The registry NCT05499013 remains ACTIVE_NOT_RECRUITING in the December 19, 2025 record and covers 69 actual participants across Phase 1 and Phase 2, distinct from the 48-patient randomized Phase 2 disclosure. Estimated primary completion September 2026 and overall completion March 2030 do not postpone the already announced August topline or establish the congress date. The company’s Phase 3 Q12W plan remains future development rather than an ongoing registrational trial.

04The Phase 1 Evidence Behind The Phase 2

On June 11, 2026 Silence presented follow-up Phase 1 data at the EHA Congress. These historical Phase 1 results preceded the positive August Phase 2 readout; the next replication test is Phase 3, and they are worth stating precisely because most secondary coverage rounds them.

The reduction from 80 phlebotomies to five is the headline, and it is a large effect. The median time to first phlebotomy of 287 days is arguably the more useful number, because it describes durability rather than suppression: nine and a half months without a procedure, in a disease where the alternative is a recurring appointment.

The caveats are the ordinary ones for a Phase 1. Twenty-one patients is a small sample, the design is open-label rather than controlled, and the pre-treatment period is a historical comparison within the same patients rather than a randomised control arm. Effects of that size in a small open-label study regularly shrink when a control group is introduced. They do not always shrink to nothing, which is why controlled replication was needed; positive Phase 2 results are now known and Phase 3 remains future.

05Zerlasiran: Phase 3-Ready And Unpartnered

Zerlasiran is an siRNA targeting lipoprotein(a), a genetically determined lipid particle that is an independent cardiovascular risk factor and for which no approved lowering therapy exists. The commercial logic is obvious and the competitive field is not empty: several large companies are running outcomes trials in the same target.

Silence describes the asset as Phase 3-ready and states that it is seeking a development partner. That sentence carries the whole financial argument of the company. A cardiovascular outcomes trial in an unapproved target is a multi-year, multi-hundred-million-dollar programme. Even after the offering, a cardiovascular outcomes program would compete directly with divesiran Phase 3 for capital; a development partner remains the economically disciplined path.

Completion of zerlasiran Phase 3 readiness work in 2025 reduced R&D spending; it does not mean all maintenance, partnering or future trial costs have ended. A signed development agreement and its economics remain unconfirmed.

06SLN312 And The AstraZeneca Return

On March 4, 2026 AstraZeneca decided not to develop SLN312 beyond Phase 1, and Silence regained full global rights to the asset. Phase 1 data were accepted for a late-breaking oral presentation at the EAS Congress held May 24-27, 2026.

There are two readings of this event and both are legitimate. The negative reading is straightforward: a large pharmaceutical partner examined the Phase 1 data and chose not to continue, which is information about the asset even when no reason is disclosed. The positive reading is that a returned asset with presentable Phase 1 data costs Silence nothing to hold and can be re-partnered or shelved at will.

What it is not is a source of near-term value. SLN312 is a third asset in a company that cannot fund its second. It belongs in the pipeline table and not in the investment case.

07Q2 2026 Financial Results

Silence reported Q2 results on August 10, the same day as the SANRECO topline. The cost base remained below the prior year as zerlasiran Phase 3-readiness spending stayed off the income statement.

First-half revenue was US$0.422 million, confirming that collaboration income is not an operating base. The fall in R&D and net loss reflects completed development work and the timing of programs; it should not be extrapolated after a Phase 3 start. The company also highlighted preclinical SLN365 and SLN098 as potential 2027 IND candidates, which could add spend alongside divesiran.

The per-share figure is reported on ordinary shares. Because one ADS represents three ordinary shares, readers should not compare the US$0.09 ordinary-share loss directly with the Nasdaq ADS price.

08 Reported cash and estimated net financing bridge

June 30 cash and equivalents were $72.054M, with no short-term investments remaining, versus $85.114M combined at December 31. H1 operating cash use was $14.085M, down from $34.093M; net loss was $27.225M. Cash conversion benefited from collection of R&D credits and working-capital movements, so historical operating use is not a steady Phase 3 budget.

The closing announcement confirms 14,907,407 ADS at $13.50 including the full option, about $201.3M gross. The prospectus estimated $188.7M net with full exercise after underwriting commissions and estimated expenses. Adding $188.7M to June cash gives approximately $260.8M before spending and other movements after June 30. This is an analyst arithmetic bridge using estimated net proceeds, not reported September cash. The old gross bridge near $273.4M overstated deployable proceeds by fees.

The 10-Q forecasts June resources into 2028 under the then-current plan, excluding unearned milestones and future financings. The August raise strengthens that position, but no longer runway date is invented here. Registration-scale trial spending, manufacturing, the extension and other candidates can increase costs. June contract liabilities of $55.218M largely represent deferred collaboration revenue, not bank debt or unrestricted incremental cash to add to the balance.

SEC · 10-Q · SEC · net proceeds estimate · IR · closing

09 ADS ratio, completed issuance and dilution

One ADS represents three ordinary shares. The latest pre-offering cover count is 141,740,037 ordinary shares at July 31, equivalent to 47,246,679 ADS. Adding the confirmed 14,907,407 ADS issued in August yields 186,462,258 ordinary shares or 62,154,086 ADS equivalents before other intervening changes. This is a derived post-offering base, not a newly filed September count. At the September 4 Marketstack close of $14.59 it implies approximately $906.83M basic equity value; Finviz’s $906.77M is consistent within vendor timing/rounding differences.

Share expansion and ownership dilution use different denominators. Neither is fully diluted: the June prospectus exclusions include 11,552,202, 10,088,736, 1,353,330 and 69,999 ordinary shares linked to outstanding options/conditional awards across plans, approximately 23.064M in total, plus ungranted plan reserves separately. Do not multiply the ADS price by ordinary shares without dividing by three. The offering closed August 14; the prior expected August 13 settlement and unexercised-option scenarios are superseded.

SEC · cover count · SEC · offering terms · IR · closing

10 Current market data and ownership disclosures

The August 13 Griffiths Form 4 reports eleven August 10 sales across controlled entities and personal holdings, totaling 5,484,320 ADS equivalents, representing 16,452,960 ordinary shares, at reported prices from $15.58 to $16.35. These are code S disposals, not the company’s primary offering or a new issue of those same securities. The filing does not identify them as mandatory tax-cover sales; no motive is inferred. June/July analyst targets in the previous version predated SANRECO and the enlarged share base and are not treated as current valuation guidance.

SEC · Griffiths Form 4

11 Retail sentiment and upcoming presentations

StockTwits on September 6 reports canonical sentiment 44/100, bearish; message activity 50/100, normal; 567 watchers. The 33.33% bullish / 66.67% bearish tagged subset is separate from the canonical score. Recent messages discuss post-data selling, option volatility and possible medical presentations. Their specific December dates, trading claims and expectations are not substituted for company guidance. No confirmed SANRECO congress date was established in the primary sources reviewed.

These September investor presentations are confirmed company events, not promised new clinical readouts. The next development milestone remains Phase 3 initiation in H1 2027, subject to regulatory alignment and execution.

IR · September 2 schedule · StockTwits · $SLN

12What Bulls See

Randomized proof, not a historical comparison. SANRECO’s 88% versus 19% responder result and p<0.0001 materially strengthen the Phase 1 signal.

Both schedules worked. The 81.3% response on Q12W supports a commercially attractive quarterly regimen while Q6W reached 93.8%.

Benefit across multiple dimensions. Phlebotomies, haematocrit, ferritin and patient-reported symptoms all moved in the intended direction.

No new safety finding in Phase 2. Injection reactions were described as infrequent and self-limiting, with only two investigator-reported Grade 1 anaemia cases.

Phase 3 financing risk is lower. The completed offering brought $201.3M gross, approximately $188.7M net estimated and can fund development from strength.

Additional optionality remains. Zerlasiran is Phase 3-ready and unpartnered, while SLN365 and SLN098 could enter the clinic in 2027.

13What Bears See

The study is still small. Forty-eight patients cannot define uncommon safety, long-term adherence or a registrational effect size.

Q12W was numerically below Q6W. The convenience advantage is valuable only if Phase 3 preserves sufficient efficacy.

The completed offering expanded the July ADS-equivalent base by 31.55%, implying 23.98% ownership dilution without participation. The June-cash-plus-estimated-net-proceeds bridge is about $260.8M before later spending; it is not current reported cash.

Phase 3 spend will reverse the lean cost base. Recent R&D reflects completed programs, not the cost of a registrational haematology study plus preclinical expansion.

Zerlasiran remains unpartnered and SLN312 was returned. Positive divesiran data do not validate every platform asset or guarantee attractive licensing economics.

Full SANRECO detail is pending. Confidence intervals, subgroup consistency, detailed safety and durability will matter when presented at a medical meeting and in the extension.

14Scenario Framework

These scenarios organize the post-SANRECO path; they are not forecasts, price targets or recommendations.

The middle path is a viable Phase 3 program with a real effect but more modest differentiation than the topline implies. In that case the value debate moves to trial design, time to registration, commercial positioning and disciplined use of the offering proceeds.

15Bottom Line

Silence delivered the two events that the pre-readout hub could not assume: a positive controlled Phase 2 and a financing large enough to support the next stage. The 88% versus 19% responder rate, 0.2 versus 2.1 mean phlebotomies and useful Q12W activity make divesiran a credible Phase 3 asset rather than an interesting Phase 1 signal.

The completed offering expanded the July ADS-equivalent base by 31.55%, implying 23.98% ownership dilution without participation. The June-cash-plus-estimated-net-proceeds bridge is about $260.8M before later spending; it is not current reported cash.

The disciplined classification is now positive proof with execution still outstanding. The decisive checkpoints are detailed SANRECO data, long-term safety and anaemia, regulatory agreement, the 1H27 Phase 3 start, cash deployment and any zerlasiran partnership. This is an educational framework, not a recommendation to buy, sell or hold $SLN.

SEC · Q2 2026 · SEC · prospectus · IR · closing · IR · September events · IR · SANRECO

Verified September 6, 2026. Clinical data are company topline results; no regulatory approval or head-to-head superiority is implied.